Clinical Trials
29 trialsNCT02101853 2026-06-03
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02112916 2026-06-03
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02306161 2026-06-03
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03811002 2026-06-01
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04092283 2026-05-29
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02003222 2026-05-28
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04624204 2026-05-26
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT00734877 2026-05-22
TT4B
University of Arkansas
Phase 3 Active not recruiting
NCT06564844 2026-05-22
TROPION-Lung12
AstraZeneca
Phase 3 Active not recruiting
NCT04380636 2026-05-15
MK-7339-012
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03017326 2026-05-13
PHITT
University of Birmingham
Phase 3 Active not recruiting
NCT06230224 2026-05-11
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT02176967 2026-05-05
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
Children's Oncology Group
Phase 3 Active not recruiting
NCT03182244 2026-05-05
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT03007147 2026-05-04
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Active not recruiting
NCT03043872 2026-04-22
CASPIAN
AstraZeneca
Phase 3 Active not recruiting
NCT02845882 2026-03-18
LBL-2016 for Children or Adolescents in China
Children's Cancer Group, China
Phase 3 Active not recruiting
NCT05091567 2026-03-10
IMforte
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04665856 2026-02-13
SKYSCRAPER-02C
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT00572169 2026-02-05
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
University of Arkansas
Phase 3 Active not recruiting
NCT03020030 2026-01-22
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT03533582 2025-12-22
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
Children's Oncology Group
Phase 3 Active not recruiting
NCT04833114 2025-09-30
Pola-R-ICE
GWT-TUD GmbH
Phase 3 Active not recruiting
NCT02521493 2025-08-01
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Children's Oncology Group
Phase 3 Active not recruiting
NCT05298423 2025-08-01
KEYVIBE-006
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05224141 2025-07-08
KEYVIBE-008
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT00470223 2025-06-08
OS2006
UNICANCER
Phase 3 Active not recruiting
NCT02375204 2025-01-13
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT05566041 2024-10-31
REPLATINUM
EpicentRx, Inc.
Phase 3 Active not recruiting